Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

× No keyword cloud information.

12 in total

Review 1. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors: Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal: World J Hepatol Date: 2015-03-27

Review 2. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors: Shunsuke Mori; Shigetoshi Fujiyama
Journal: World J Gastroenterol Date: 2015-09-28 Impact factor: 5.742

Review 3. Efficacy and safety of rituximab in rheumatic diseases.

Authors: Eva Rath; Jochen Zwerina; Bastian Oppl; Valerie Nell-Duxneuner
Journal: Wien Med Wochenschr Date: 2015-01-21

Review 4. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.

Authors: Dimitrios Vassilopoulos; Leonard H Calabrese
Journal: Curr Rheumatol Rep Date: 2013-04 Impact factor: 4.686

Review 5. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors: Masaru Kato; Tatsuya Atsumi
Journal: Rheumatol Int Date: 2015-11-16 Impact factor: 2.631

6. Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection.

Authors: Michele Barone; Vincenzo Venerito; Rosa Paolillo; Giacomo Emmi; Marco Fornaro; Fabio Cacciapaglia; Luca Cantarini; Alfredo Di Leo; Florenzo Iannone; Giuseppe Lopalco
Journal: Intern Emerg Med Date: 2021-09-02 Impact factor: 3.397

7. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.

Authors: Mary Jane Burton; Jeffrey R Curtis; Shuo Yang; Lang Chen; Jasvinder A Singh; Ted R Mikuls; Kevin L Winthrop; John W Baddley
Journal: Arthritis Res Ther Date: 2015-05-22 Impact factor: 5.156

Review 8. Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors: Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal: Rheumatol Int Date: 2014-12-31 Impact factor: 2.631

Review 9. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Authors: Md Yuzaiful Md Yusof; Edward M Vital; Maya H Buch
Journal: Curr Rheumatol Rep Date: 2015-10 Impact factor: 4.592

Review 10. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.

Authors: Soheil Tavakolpour; Seyed Moayed Alavian; Shahnaz Sali
Journal: Hepat Mon Date: 2016-03-26 Impact factor: 0.660